Holen Sie sich die Stockscreener-App
1.07
3.88%
0.04
Handel nachbörslich:
1.07
Schlusskurs vom Vortag:
$1.03
Offen:
$1.05
24-Stunden-Volumen:
349.59K
Relative Volume:
0.65
Marktkapitalisierung:
$91.53M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-49.87M
KGV:
-0.5448
EPS:
-1.964
Netto-Cashflow:
$-19.36M
1W Leistung:
+7.54%
1M Leistung:
-35.54%
6M Leistung:
-30.52%
1J Leistung:
-47.80%
1-Tages-Spanne:
$1.02
$1.08
1-Wochen-Bereich:
$0.9502
$1.08
52-Wochen-Spanne:
$0.9502
$2.21
Rein Therapeutics Inc Stock (RNTX) Company Profile
Firmenname
Rein Therapeutics Inc
Sektor
Branche
Telefon
(737) 802-1989
Adresse
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.07 | 88.11M | 0 | -49.87M | -19.36M | -1.964 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-07-24 | Eingeleitet | BofA/Merrill | Buy |
| 2017-07-24 | Eingeleitet | Jefferies | Buy |
| 2017-07-24 | Eingeleitet | William Blair | Outperform |
Rein Therapeutics Inc Aktie (RNTX) Neueste Nachrichten
RNTX Q1 2026 Earnings: EPS Beats Estimates as Preclinical Stage Biotech Tightens SpendingAnalyst Consensus Shift - Newser
RNTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Rein Therapeutics Advances PipelineProfit Growth Outlook - Newser
Rein Therapeutics (RNTX) Surges 7% as Stock Tests Key Resistance at $1.09Community Risk Signals - newser.com
Rein Therapeutics (RNTX) Q1 2026 Earnings Surprise: EPS $-0.19, Up SignificantHigh Estimate Range - Newser
Rein Therapeutics announces closing of $57.5 million underwritten public offering - marketscreener.com
Rein Therapeutics Announces Closing Of $57.5 Million Underwritten Public Offering - TradingView
Rein Therapeutics closes $57.5 million stock offering - Investing.com
Rein Therapeutics closes $57.5 million stock offering By Investing.com - Investing.com Canada
Biotech Rein Therapeutics raises $57.5M for lung fibrosis trial - Stock Titan
Rein Therapeutics, Inc. Q1 2026 10-Q Report: Financial Statements, Risk Factors, and Forward-Looking Statements - Minichart
Rein Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Rein Therapeutics, Inc. 1Q 2026: Revenue $0 Net loss $(5.84)M, EPS $(0.19) — 10-Q Summary - TradingView
Rein Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
RNTX Technical Analysis | Trend, Signals & Chart Patterns | REIN THERAPEUTICS INC (NASDAQ:RNTX) - ChartMill
Rein Therapeutics CEO Windsor buys $25,000 in common stock By Investing.com - Investing.com Nigeria
Rein Therapeutics CEO Windsor buys $25,000 in common stock - Investing.com
Rein Therapeutics (RNTX) quarterly results lack key metrics as company navigates strategic positioning, investors await clarityMomentum Score - newser.com
Number of shareholders of Rein Therapeutics, Inc. – NASDAQ:RNTX - TradingView
Rein Therapeutics, Inc. News — NASDAQ:RNTX - TradingView
Should you add Rein Therapeutics (RNTX) to your watchlist today? (Trend Strengthens) 2026-05-08Viral Trade Signals - newser.com
Bios/Cavu investors disclose ~9.99% stake in Rein Therapeutics (RNTX) via preferred conversions - Stock Titan
Lynwood group owns 4.75M Rein Therapeutics (RNTX) shares (6.1%) - Stock Titan
Funicular Funds holds 5.195M shares in Rein Therapeutics (RNTX) — 6.7% - Stock Titan
Rein Therapeutics(RNTX) Stock Options Chain | Quotes & News - Moomoo
L. Lytton reports 4.5M shares in Rein Therapeutics (NASDAQ: RNTX) - Stock Titan
Rein Therapeutics, Inc.Common Stock (Nasdaq:RNTX) Stock Quote - The Chronicle-Journal
Rein Therapeutics Prices $50 Million Public Equity Offering - TipRanks
Rein Therapeutics (NASDAQ: RNTX) raises $50M, funds IPF trial into 2028 - Stock Titan
Rein Therapeutics (NASDAQ: RNTX) to sell 50M shares, nets ~$46.1M - Stock Titan
Rein Therapeutics stock dips after pricing $50M share offering - MSN
RNTX Slides As Rein Therapeutics Stock Tests New Lows - timothysykes.com
RNTX Stock Dips As Traders Weigh Deep Losses And Cash Runway - StocksToTrade
Rein Therapeutics Prices $50 Million Common Stock Offering; Shares Down Pre-Bell - Moomoo
Rein Therapeutics | EFFECT: Others - Moomoo
RNTX Stock Slides As Traders Eye Heavy Losses - timothysykes.com
Rein Therapeutics prices $50 million public offering at $1 - Investing.com
Rein Therapeutics prices $50 million public offering at $1 By Investing.com - Investing.com South Africa
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Rein Therapeutics, Inc. Announces Pricing of $50 Million Public Offering of Common Stock - Quiver Quantitative
Rein Therapeutics Inc prices public offering of 50 million shares at $1.00 per share for $50 million - marketscreener.com
Rein's $50M stock sale backs Phase 2 lung fibrosis study - Stock Titan
Rein Therapeutics Inc Prices Public Offering Of 50 Million Shares At $1.00 Per Share For $50 Million - TradingView
Rein Therapeutics' 50M-Share Offering Prices at $1 a Share - Moomoo
RNTX (Rein Therapeutics) shares drop 12 percent after Q4 2025 EPS misses analyst estimates by a massive margin.Crowd Breakout Signals - Newser
Rein Therapeutics provides clinical trial update for Phase 2 ReNEW Study of LTI-03 in idiopathic pulmonary fibrosis - marketscreener.com
RNTX - Finviz
Rein Therapeutics Provides Clinical Trial Update For Phase 2 Renew Study Of Lti-03 In Idiopathic Pulmonary Fibrosis - TradingView
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis - ChartMill
Rein Therapeutics (RNTX) to sell 30M shares to fund LTI‑03 trial - Stock Titan
Is Rein Therapeutics (RNTX) stock testing important levels | Q4 2025: Profit DisappointsCommunity Sell Signals - Newser
Rein Therapeutics, Inc. 2025 Executive Compensation, Director Pay, and Governance Details (10-K/A) - Minichart
Finanzdaten der Rein Therapeutics Inc-Aktie (RNTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rein Therapeutics Inc-Aktie (RNTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Voss Capital, LP | 10% Owner |
Nov 14 '25 |
Buy |
1.22 |
104,183 |
127,593 |
926,441 |
| Voss Capital, LP | 10% Owner |
Oct 28 '25 |
Buy |
1.39 |
178,392 |
247,965 |
500,000 |
| Voss Capital, LP | 10% Owner |
Oct 27 '25 |
Buy |
1.37 |
97,482 |
133,544 |
822,258 |
| Voss Capital, LP | 10% Owner |
Oct 24 '25 |
Buy |
1.39 |
30,176 |
41,957 |
729,616 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):